{
    "clinical_study": {
        "@rank": "94255", 
        "arm_group": [
            {
                "arm_group_label": "Benralizumab Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Benralizumab administered subcutaneously every 4 weeks"
            }, 
            {
                "arm_group_label": "Benralizumab Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered subcutaneously every 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to confirm if benralizumab can reduce OCS dependence (after\n      dose optimisation) in patients who are uncontrolled on high-dose ICS-LABA, and chronically\n      dependent on OCS as part of their regular asthma controller regimen."
        }, 
        "brief_title": "Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Provision of informed consent prior to any study specific procedures\n\n          2. Female and male aged from 18 to 75 years, inclusively\n\n          3. History of physician-diagnosed asthma requiring treatment with medium dose ICS  and a\n             LABA\n\n          4. Elevated level of peripheral blood eosinophil\n\n          5. Documented treatment with high-dose ICS and LABA for at least 6 months prior to Visit\n             1\n\n          6. Chronic oral prednisone or prednisolone therapy for at least 6 continuous months\n             directly preceding Visit 1, and on a stable dose for at least one month prior to\n             Visit 1\n\n          7. Patients with documented failures of OCS reduction within 6 months prior to Visit 1\n             will not be required to proceed through the dose optimization phase during run-in.\n\n          8. Morning pre-bronchodilator (Pre-BD) FEV1 of <80% predicted\n\n          9. Either documented post bronchodilator (post-BD) reversibility of \u2265 12% and \u2265 200 mL\n             in FEV1 or PC20 FEV1\n\n         10. At least 1 documented asthma exacerbation in the previous 12 months prior to the date\n             informed consent is obtained\n\n         11. Optimized OCS dose reached at least 2 weeks prior to randomization\n\n         12. Additional asthma controller medication must not have been initiated during run-in\n             period\n\n         13. At least 70% compliance with OCS use\n\n         14. At least 70% compliance with usual asthma controller ICS-LABA\n\n         15. Minimum 70% (i.e. 10 of 14 days) compliance with asthma daily diary (morning and\n             evening diary)\n\n         16. No documented asthma exacerbations during the screening/dose optimization period\n\n        Exclusion criteria:\n\n          1. Clinically important pulmonary disease other than asthma or ever been diagnosed with\n             pulmonary or systemic disease, other than asthma, that are associated with elevated\n             peripheral eosinophil counts.\n\n          2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal,\n             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,\n             haematological, psychiatric, or major physical impairment that is not stable in the\n             opinion of the Investigator and could:\n\n               -  Affect the safety of the patient throughout the study\n\n               -  Influence the findings of the studies or their interpretations\n\n               -  Impede the patient's ability to complete the entire duration of study\n\n          3. Acute upper or lower respiratory infections requiring antibiotics or antiviral\n             medication within 30 days prior to the date informed consent is obtained or during\n             the screening/run-in period\n\n          4. Any clinically significant abnormal findings in physical examination, vital signs,\n             haematology, clinical chemistry, or urinalysis during screening/run-in period, which\n             in the opinion of the Investigator, may put the patient at risk because of his/her\n             participation in the study, or may influence the results of the study, or the\n             patient's ability to complete entire duration of the study\n\n          5. History of life-threatening asthma\n\n          6. Asthma control reached at an OCS dose of \u22645mg during run-in/OCS optimization phase\n\n          7. Qualifies for 3 consecutive dose reductions at Visits 2-4 and continues to meet OCS\n             dose reduction criteria at Visit 5\n\n          8. Receipt of oral dexamethasone as the maintenance oral steroid controller for asthma\n             symptoms"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075255", 
            "org_study_id": "D3250C00020"
        }, 
        "intervention": [
            {
                "arm_group_label": "Benralizumab Arm A", 
                "description": "Benralizumab administered subcutaneously every 4 weeks", 
                "intervention_name": "Benralizumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo subcutaneously on study week 0 until study week 24 inclusive.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Benralizumab Arm B", 
                "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.", 
                "intervention_name": "Benralizumab", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases, OCS, Oral Corticosteroids", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hialeah", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston Salem", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middleburg Heights", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caba", 
                        "country": "Argentina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Florida", 
                        "country": "Argentina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quillota", 
                        "country": "Chile"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Talcahuano", 
                        "country": "Chile"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grosshansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Canada", 
                "Chile", 
                "Germany"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Clinical Trial Transparency"
        }, 
        "overall_contact_backup": {
            "email": "information.center@astrazeneca.com", 
            "last_name": "Clinical Study Information", 
            "phone": "+1 800-236-9933"
        }, 
        "overall_official": {
            "affiliation": "St Joseph's Healthcare Hamilton Firestone Institute for Respiratory Health 50 Charlton Avenue East Hamilton", 
            "last_name": "Parameswaran Nair, MD,PhD,FRCP,FRCPC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Canada: Health Canada", 
                "Chile: Instituto de Salud P\u00fablica de Chile", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Germany: Paul-Ehrlich-Institut", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "France: National Agency for Medicine and Health Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The effect of 2 dosing regimens of benralizumab on percentage reduction of Oral Corticosteroid dose in the terms of percentage reduction in final Oral Corticosteroid dose compared with week 0, while maintaining asthma control", 
            "safety_issue": "No", 
            "time_frame": "Starting from week 0 following the first administration of study drug through study week 28."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075255"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on Oral Corticosteroid dose in the terms of proportion of patients with \u226550% reduction in average daily Oral Corticosteroid dose at week 28 compared with dose at week 0 while maintaining asthma control", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on Oral Corticosteroid dose in the terms of proportion of patients with average final Oral Corticosteroid dose \u22645.0 mg daily at week 28, while maintaining asthma control.", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on Oral Corticosteroid dose in the terms of proportion of patients with \u22645.0 mg reduction on daily Oral Corticosteroid dose at week 28 compared with dose at week 0, while maintaining asthma control.", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on parameters associated with asthma exacerbations in the terms of proportion of patients with \u22651 asthma exacerbation after randomization", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on parameters associated with asthma exacerbations in the terms of time to the first asthma exacerbation after randomization", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on parameters associated with asthma exacerbations in the terms of annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization after randomization", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in prebronchodilator Forced Expiratory Volume in 1 second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in prebronchodilator Inspiratory Capacity (IC).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Expiratory Reserve Volume (ERV).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Inspiratory Reserve Volume (IRV).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Inspiratory Vital Capacity (VCIN).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Expiratory Vital Capacity (VCEX).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on pulmonary function in the terms of change from week 0 in Maximum Vital Capacity (VCMAX).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in asthma symptom score (total, daytime, and night time).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in rescue medication use.", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in home lung function (morning and evening Peak Expiratory Flow (PEF)).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in the number of nights with awakening due to asthma requiring rescue medication.", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on asthma symptoms and other asthma control metrics in the terms of change from week 0 in Asthma Control Questionnaire 6 (ACQ-6).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on asthma related health-related quality of life in the terms of change from week 0 in Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12).", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The pharmacokinetics (PK) of 2 dosing regimens of benralizumab in the terms of PK parameters", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The immunogenicity of 2 dosing regimens of benralizumab in the terms of Anti-drug antibodies (ADA) presence or absence", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The safety and tolerability of 2 dosing regimens of benralizumab in the terms of Adverse Event (AE)/Serious Adverse Event (SAE)", 
                "safety_issue": "Yes", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The safety and tolerability of 2 dosing regimens of benralizumab in the terms of laboratory variables", 
                "safety_issue": "Yes", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The safety and tolerability of 2 dosing regimens of benralizumab in the terms of electrocardiogram (ECG) evaluation", 
                "safety_issue": "Yes", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The safety and tolerability of 2 dosing regimens of benralizumab in the terms of physical examination results", 
                "safety_issue": "Yes", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on blood eosinophil count.", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on blood eosinophil levels (subset of patients) in the terms of assessment of eosinophil progenitor cells", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on sputum differential cell count (subset of patients) in the terms of sputum cell differential count", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on biomarkers (subset of patients) in the terms of quantification of sputum cytokines and biomarkers", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on sputum differential cell count (subset of patients) in the terms of assessment of eosinophil progenitor cells", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The effect of 2 dosing regimens of benralizumab on blood biomarkers in the terms of quantification of serum biomarkers.", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Total Lung Capacity (TLC)", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Residual Volume (RV)", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Vital Capacity (VC)", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Inspiratory Capacity (IC)", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }, 
            {
                "measure": "The impact of 2 dosing regimens of benralizumab on lung function as assessed thru body plethysmography (subset of patients) in the terms of Functional Residual Capacity (FRC)", 
                "safety_issue": "No", 
                "time_frame": "From week 0 to week 28 in study treatment phase"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}